 Sezary Syndrome
"Sezary Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).
| Descriptor ID |
D012751
|
| MeSH Number(s) |
C04.557.386.480.750.800.775 C15.604.515.569.480.750.800.775 C15.604.515.841 C20.683.515.761.480.750.800.775 C20.683.515.920
|
| Concept/Terms |
Sezary Syndrome- Sezary Syndrome
- Syndrome, Sezary
- Sezary's Lymphoma
- Lymphoma, Sezary's
- Sezary Lymphoma
- Sezarys Lymphoma
- Erythroderma, Sezary
- Sezary Erythroderma
|
Below are MeSH descriptors whose meaning is more general than "Sezary Syndrome".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Sezary Syndrome [C04.557.386.480.750.800.775]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Sezary Syndrome [C15.604.515.569.480.750.800.775]
- Sezary Syndrome [C15.604.515.841]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
- Sezary Syndrome [C20.683.515.761.480.750.800.775]
- Sezary Syndrome [C20.683.515.920]
Below are MeSH descriptors whose meaning is more specific than "Sezary Syndrome".
This graph shows the total number of publications written about "Sezary Syndrome" by people in this website by year, and whether "Sezary Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sezary Syndrome" by people in Profiles.
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
-
Kremer KN, Dinkel BA, Sterner RM, Osborne DG, Jevremovic D, Hedin KE. TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL. Blood. 2017 08 24; 130(8):982-994.
-
Bunn PA, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl. 1996; 24:12-23.
-
Bunn PA. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy? Arch Dermatol. 1995 May; 131(5):603-5.
-
Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the S?zary syndrome). Ann Intern Med. 1994 Oct 15; 121(8):592-602.
-
Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and S?zary syndrome. Oncology (Williston Park). 1992 Feb; 6(2):31-42; discussion 44, 47-8.
-
Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S.
-
Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks SR, Bunn PA. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):208-12.
-
Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S?zary syndrome. J Clin Oncol. 1990 Jan; 8(1):155-60.
-
Dmitrovsky E, Matthews MJ, Bunn PA, Schechter GP, Makuch RW, Winkler CF, Eddy J, Sausville EA, Ihde DC. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol. 1987 Feb; 5(2):208-15.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|